Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026
Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPC No dose-limiting toxicities observed; xerostomia has been predominantly Grade 1, with no cases of Grade 3 100% of lutetium-177-naive patients achieved PSA50, 88.9%...
Covered in this story
Call it yourself
No calls on $PSA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Public Storage →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.